Results 31 to 40 of about 454,650 (72)

Comprehensive metabolomics expands precision medicine for triple-negative breast cancer

Cell Research, 2022
Metabolic reprogramming is a hallmark of cancer. However, systematic characterizations of metabolites in triple-negative breast cancer (TNBC) are still lacking.
Yi Xiao, D. Ma, Yun-Song Yang, Fan Yang, Jianlong Ding, Y. Gong, Linbailu Jiang, Li-Ping Ge, Song-Yang Wu, Qiang Z. Yu, Qing Zhang, F. Bertucci, Qiuzhuang Sun, Xin Hu, Da-Qiang Li, Z. Shao, Yizhou Jiang   +16 more
semanticscholar   +1 more source

Industry 4.0 and sustainable development: A systematic mapping of triple bottom line, Circular Economy and Sustainable Business Models perspectives

Journal of Cleaner Production, 2021
Industry 4.0 has been identified as a major contributor to the era of digitalisation. Its implications for sustainable development have gained widespread attention from the perspectives of the triple bottom line, sustainable business models and circular ...
Iqra Khan, M. Ahmad, J. Majava
semanticscholar   +1 more source

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

The Lancet, 2020
BACKGROUND Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer.
J. Cortés, D. Cescon, H. Rugo, Z. Nowecki, S. Im, M. Yusof, C. Gallardo, O. Lipatov, C. Barrios, E. Holgado, H. Iwata, N. Masuda, M. Otero, E. Gokmen, S. Loi, Zifang Guo, Jingyi Zhao, G. Aktan, V. Karantza, P. Schmid   +19 more
semanticscholar   +1 more source

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.

New England Journal of Medicine
BACKGROUND In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition of pembrolizumab to platinum-containing ...
P. Schmid, J. Cortés, R. Dent, H. McArthur, L. Pusztai, S. Kümmel, C. Denkert, Y. Park, R. Hui, N. Harbeck, M. Takahashi, Seock-Ah Im, M. Untch, P. Fasching, M. Mouret-Reynier, T. Foukakis, M. Ferreira, F. Cardoso, Xuan Zhou, V. Karantza, K. Tryfonidis, G. Aktan, J. O’Shaughnessy   +22 more
semanticscholar   +1 more source

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

Nature Medicine
Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8 and 12 mg ...
Arun J. Sanyal, Lee M Kaplan, J. P. Frias, B. Brouwers, Qiwei Wu, M. Thomas, C. Harris, N. C. Schloot, Yu Du, K. Mather, A. Haupt, M. Hartman   +11 more
semanticscholar   +1 more source

Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer

New England Journal of Medicine, 2018
Background Unresectable locally advanced or metastatic triple‐negative (hormone‐receptor–negative and human epidermal growth factor receptor 2 [HER2]–negative) breast cancer is an aggressive disease with poor outcomes.
P. Schmid, S. Adams, H. Rugo, A. Schneeweiss, C. Barrios, H. Iwata, V. Diéras, R. Hegg, S. Im, G. Shaw Wright, V. Henschel, L. Molinero, S. Chui, R. Funke, A. Husain, E. Winer, S. Loi, L. Emens   +17 more
semanticscholar   +1 more source

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

The Lancet, 2020
Summary Background Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir–ritonavir, and ribavirin for treating patients with ...
I. Hung, K. Lung, E. Tso, R. Liu, T. Chung, M. Chu, Y. Ng, J. Lo, Jacky Chan, A. Tam, H. Shum, V. Chan, A. Wu, K. Sin, W. Leung, W. Law, D. Lung, Si-Ok Sin, Pauline Yeung, C. Yip, R. Zhang, Agnes Yim-Fong Fung, Erica Yuen-Wing Yan, Kit-Hang Leung, J. D. Ip, A. W. Chu, W. Chan, A. C. Ng, R. Lee, K. Fung, A. Yeung, Tak-chiu Wu, J. Chan, W. Yan, W. Chan, Jasper Fuk Woo Chan, A. Lie, O. Tsang, V. Cheng, T. Que, C. Lau, Kwok-Hung Chan, K. To, K. Yuen   +43 more
semanticscholar   +1 more source

Innovative Capacity in Triple Helix Partnerships: an Assessment of Conditions for Social Learning

Triple Helix
The Triple Helix (3H) model has attracted considerable attention in both developed and emerging economies as a tool to enhance innovation for economic development (Etzkowitz and Leydesdorff, 2000).
H. Mudde, Alemfrie Derese Chekole, Madeleine Lauer   +2 more
semanticscholar   +1 more source

Cesium-containing triple cation perovskite solar cells: improved stability, reproducibility and high efficiency

Energy & Environmental Science, 2016
Today's best perovskite solar cells use a mixture of formamidinium and methylammonium as the monovalent cations. Adding cesium improves the compositions greatly.
Michael Saliba, Taisuke Matsui, Ji‐Youn Seo, Konrad Domanski, Juan‐Pablo Correa‐Baena, M. Nazeeruddin, S. M. Zakeeruddin, W. Tress, A. Abate, A. Hagfeldt, M. Graetzel   +10 more
semanticscholar   +1 more source

Critical Success Factors for Implementing Triple Helix Collaborations in a Developing Country Context

Triple Helix
The purpose of this study was to get an understanding of the local context for implementing triple helix collaborations in a developing economic context, Zambia in this case. Many African countries are still unable to synthesise research evidence for
Joseph Phiri
semanticscholar   +1 more source